Market Overview

Raptor Announces Phase 2b Trial of RP103 for NAFLD in Children Meets Enrollment Target


Raptor Pharmaceutical (Nasdaq: RPTP) today announced that its Phase 2b clinical trial, to evaluate the safety and potential efficacy of RP103 delayed-release cysteamine bitartrate as a prospective treatment of non-alcoholic fatty liver disease (NAFLD) in children, has met its enrollment target.

See full press release

Posted-In: News Guidance Contracts Management Global


Related Articles (RPTP)

View Comments and Join the Discussion!